Welcome to our dedicated page for XOMA Royalty Corporation news (Ticker: XOMA), a resource for investors and traders seeking the latest updates and insights on XOMA Royalty Corporation stock.
XOMA Corporation (NASDAQ: XOMA) is a biotechnology royalty aggregator that plays a pivotal role in accelerating the development of groundbreaking therapeutic candidates. With an extensive portfolio of over 70 assets, XOMA acquires potential future economics associated with pre-commercial and commercial therapeutic candidates licensed to pharmaceutical or biotech companies. This unique model enables XOMA to provide non-dilutive, non-recourse funding to its partners, helping them advance their internal drug candidates or cater to general corporate needs.
Notably, XOMA has pioneered in the discovery and development of antibody therapeutics, leading to over 20 licenses producing milestone and royalty payments in the future. One key asset in their portfolio is X358, an allosteric monoclonal antibody aimed at treating hyperinsulinism by reducing insulin receptor activity.
XOMA has recently expanded its portfolio through strategic acquisitions. In January 2024, the company acquired an economic interest in DSUVIA® (sufentanil sublingual tablet) from Talphera, Inc., for $8 million. DSUVIA® is an FDA-approved pain management option used in supervised medical settings. The agreement stipulates that XOMA will receive all royalties and milestones related to DSUVIA® until $20 million is accrued. Subsequently, royalties will be shared between XOMA and Talphera.
Further broadening its portfolio, XOMA acquired Kinnate Biopharma in April 2024, bringing additional assets into their royalty pipeline. Kinnate’s lead candidates include investigational pan-RAF inhibitor exarafenib and FGFR inhibitor KIN-3248, both targeting cancers with specific genetic alterations.
In April 2024, XOMA announced a $9 million milestone following the FDA approval of Day One Biopharmaceuticals’ OJEMDA™ (tovorafenib), designed to treat pediatric low-grade glioma harboring BRAF alterations. This approval marks a significant addition to XOMA's cash flow and royalty income.
Additionally, XOMA's economic interest in three of Daré Bioscience's women's health products, including the FDA-approved XACIATO™ (clindamycin phosphate) vaginal gel, Ovaprene®, and Sildenafil Cream, 3.6%, signifies their commitment to addressing underrepresented therapeutic areas with significant growth potential.
As of their latest financial results, XOMA reported strong cash reserves and a growing portfolio of commercial and development-phase assets, ensuring long-term sustainability and value creation for shareholders. The company’s disciplined approach to capital deployment and strategic acquisitions highlights its commitment to enhancing human health through biotechnology advancements.
Viracta Therapeutics (Nasdaq: VIRX) and XOMA Corporation (Nasdaq: XOMA) announced the acquisition of milestone and royalty rights for two clinical-stage drug candidates through a $13.5 million upfront payment. XOMA may pay up to $20 million in milestone payments. The candidates include DAY101, in a Phase 2 trial for pediatric glioma, and vosaroxin, aimed at treating acute myeloid leukemia. This deal is expected to provide Viracta with non-dilutive capital to support upcoming trials for Epstein-Barr virus-related cancers.
XOMA Corporation (Nasdaq: XOMA) announced a cash dividend of $0.71875 per share for its Series A Cumulative Perpetual Preferred Stock (XOMAP). The dividend will be paid on or about April 15, 2021, to shareholders on record as of the close of business on April 2, 2021. This reflects the company’s ongoing commitment to returning value to its shareholders.
XOMA has developed a diverse portfolio licensed to other biotech firms, focusing on milestone and royalty opportunities within drug development.
XOMA Corporation reported a recognized revenue of $29.4 million for 2020, a significant increase from $18.4 million in 2019. The company achieved a milestone earning of $25 million following Novartis' Phase 2 trial initiation of NIS793 for metastatic pancreatic cancer. XOMA also completed a $24.6 million Series A Preferred Stock offering, paying an 8.625% dividend. As of December 31, 2020, XOMA held $84.2 million in cash, marking a solid financial position to support future operations and projects.
On February 23, 2021, XOMA Corporation announced that CEO Jim Neal will present at two upcoming investor conferences. He will participate in a panel at the Cowen 41st Annual Virtual Health Care Conference on March 2, 2021, discussing clinical development. Additionally, XOMA will present at the H.C. Wainwright Global Life Sciences Conference, with on-demand access starting March 9, 2021. XOMA specializes in a portfolio of partnered programs and antibody therapeutics, aiming to generate milestone and royalty revenues for shareholders.
XOMA Corporation (NASDAQ: XOMA) announced that CEO Jim Neal will present at two upcoming investor conferences. The H.C. Wainwright Virtual BioConnect 2021 Conference, running from January 11-14, 2021, will feature XOMA’s presentation available on-demand starting January 11 at 6:00 AM ET. Additionally, XOMA will present at the Biotech Showcase Digital Conference from January 11-15, 2021, accessible to registered participants. Replays of these presentations will be archived for 90 days on XOMA's investor relations website.
XOMA Corporation has successfully completed an underwritten public offering of 984,000 shares of its 8.625% Series A Cumulative Perpetual Preferred Stock at $25.00 per share, raising approximately $23.4 million in net proceeds. The funds will support a segregated dividend account and general corporate purposes, including future acquisitions related to drug development programs. The Preferred Stock trades under the symbol ‘XOMAP’ on Nasdaq. XOMA continues to expand its portfolio of partner-funded drug development programs across various therapeutic areas.
XOMA Corporation announced the pricing of its public offering of 880,000 shares of 8.625% Series A Cumulative Perpetual Preferred Stock at $25.00 per share, raising gross proceeds of $22.0 million. A 30-day option allows underwriters to purchase an additional 104,000 shares. The offering is set to close on December 15, 2020, subject to conditions. Proceeds will fund a segregated dividend account and support general corporate purposes, including acquiring milestone and royalty rights for drug development programs. The shares will trade under the symbol 'XOMAP' on NASDAQ if approved.
XOMA Corporation announced a public offering of its Series A Cumulative Perpetual Preferred Stock at a liquidation preference of $25.00 per share. The offering includes a 30-day option for underwriters to purchase additional shares. Proceeds will fund a segregated dividend account and support general corporate purposes, including acquisitions of milestone and royalty rights for drug development. The offering is conducted under an effective shelf registration statement. Joint book-runners for the offering include B. Riley Securities and others.
XOMA Corporation announced a $2 million milestone payment from Takeda, marking the first patient dosed in the Phase 2 study of mezagitamab for generalized myasthenia gravis. This collaboration began in 2006, and XOMA may receive up to $16 million more in milestones. Recently, XOMA earned $28.5 million from four partners for similar milestones. The company emphasizes its growing portfolio through milestone interests and royalty rights, indicating a promising future for its royalty aggregator model.
XOMA Corporation (Nasdaq: XOMA) announced a $1 million milestone payment from Agenus related to Merck’s MK-4830, which is entering Phase 2 studies for treating advanced non-small cell lung cancer (NSCLC). This milestone marks the first achievement under XOMA's new royalty and milestone aggregator business model, having acquired a $15 million royalty interest from Agenus. CEO Jim Neal expressed optimism about this advancement's potential benefits for NSCLC patients.
FAQ
What is the current stock price of XOMA Royalty Corporation (XOMA)?
What is the market cap of XOMA Royalty Corporation (XOMA)?
What does XOMA Corporation do?
What is XOMA’s business model?
What recent acquisitions has XOMA made?
What are some key assets in XOMA's portfolio?
How does XOMA generate revenue?
What is the significance of XOMA’s investment in X358?
How does XOMA support biotech companies?
What was the financial impact of XOMA’s acquisition of DSUVIA®?
Who are some of XOMA’s partners?
What are XOMA's future plans for growth?
